Several complex dynamics are shaping the CGT sector, including a rapidly advancing pipeline, improving regulatory and policy environments, rising commercial prospects, and manufacturing advancements.
ARM’s data-driven ‘Reasons to Believe’ analysis highlights the sector's underappreciated progress, such as regulatory acceleration, a strong commercial outlook, a rapidly advancing pipeline, progress in reducing COGS, big biopharma’s long-term bets on the sector, and modernization of access frameworks. We use this analysis to engage investors and empower our members to bolster their own investor interactions.
ARM develops data-driven insights, narratives, and messaging for our member companies to leverage in their investor relationships. These resources help position the cell and gene therapy sector as an area with transformative potential and unique value.
ARM leadership meets directly with venture capital firms, institutional investors, investment banks, analysts, and other investor stakeholders to promote a deeper understanding of cell and gene therapy trends.
ARM convenes the investment community at events, such as the Meeting on the Mesa and State of the Industry Briefing, for curated content and networking.
Our team is ready to help. To engage with ARM, contact Stephen Majors at [email protected].
Sign up for ARM’s weekly newsletter on sector news and alerts for events, reports, and other engagement opportunities.
